ANI Pharmaceuticals (ANIP) has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding on worldwide net revenues of Iluvien and Yutiq for a one-time payment of $17.25M. Under the terms of the agreement, upon making the buyout payment, no further royalty is due to SWK on net revenues beginning January 1, 2025, forward. ANI funded the buyout with cash on hand.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- Positive Outlook for ANI Pharmaceuticals: FDA Approval and Strategic Moves Drive Buy Rating
- ANI Pharmaceuticals announces FDA approval for expansion of Iluvien label
- ANI Pharmaceuticals initiated with a Buy at Jefferies
- ANI Pharmaceuticals initiated with an Overweight at JPMorgan
- ANI Pharmaceuticals Discusses Alimera Acquisition Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue